GlassScriptPhysician profile
Milton E Garcia
NPI 1194820431
$6,752.63
in general payments reported to CMS, 2019-2025
21 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,525 · 2021: $244 · 2022: $402 · 2023: $667 · 2024: $2,612 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,025 · Food and Beverage: $1,557.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,025.00 |
| Food and Beverage | $1,556.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,236.97 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $2,025.00 | 2024 | |
| Fennec Pharmaceuticals, INC. | $393.05 | 2024 | Pedmark |
| Mallinckrodt Hospital Products INC. | $219.09 | 2021-2025 | Acthar, Terlivaz |
| Calliditas Therapeutics US INC. | $184.68 | 2023-2024 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $182.28 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $168.45 | 2021-2022 | |
| Nxstage Medical, INC. | $162.06 | 2023 | Nxstage System One, Liberty Select Cycler |
| Fresenius USA Marketing, INC. | $137.59 | 2019 | |
| Lilly USA, LLC | $130.99 | 2023-2025 | Mounjaro, Zepbound |
| Depuy Synthes Sales INC. | $129.21 | 2023 | Na |
| Otsuka America Pharmaceutical, INC. | $125.00 | 2023 | Jynarque |
| Medtronic Vascular, INC. | $124.71 | 2019 | |
| Glaxosmithkline, LLC. | $111.69 | 2025 | Benlysta |
| Genzyme Corporation | $89.95 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $86.18 | 2025 | |
| Bard Peripheral Vascular, INC. | $81.63 | 2022 | |
| Teleflex LLC | $50.49 | 2024 | Urolift |
| Amgen INC. | $48.76 | 2019 | |
| Edwards Lifesciences Corporation | $46.24 | 2019 | |
| Abiomed | $18.61 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milton Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.